Angiogenesis-Related Pathways in the Pathogenesis of Ovarian Cancer

被引:112
作者
Gavalas, Nikos G. [1 ]
Liontos, Michalis [1 ]
Trachana, Sofia-Paraskevi [1 ]
Bagratuni, Tina [1 ]
Arapinis, Calliope [1 ]
Liacos, Christine [1 ]
Dimopoulos, Meletios A. [1 ]
Bamias, Aristotle [1 ]
机构
[1] Univ Athens, Sch Med, Dept Clin Therapeut, Alexandra Hosp, Athens 11528, Greece
关键词
ovarian; cancer; angiogenesis; pathway; VEGF; PDGF; FGF; Ang; Tie2; ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; RECURRENT EPITHELIAL OVARIAN; TYROSINE KINASE INHIBITOR; GRADE SEROUS CARCINOMA; FALLOPIAN-TUBE CANCER; CLEAR-CELL CARCINOMA; PHASE-II TRIAL; FACTOR RECEPTOR; TUMOR ANGIOGENESIS;
D O I
10.3390/ijms140815885
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Ovarian Cancer represents the most fatal type of gynecological malignancies. A number of processes are involved in the pathogenesis of ovarian cancer, especially within the tumor microenvironment. Angiogenesis represents a hallmark phenomenon in cancer, and it is responsible for tumor spread and metastasis in ovarian cancer, among other tumor types, as it leads to new blood vessel formation. In recent years angiogenesis has been given considerable attention in order to identify targets for developing effective anti-tumor therapies. Growth factors have been identified to play key roles in driving angiogenesis and, thus, the formation of new blood vessels that assist in feeding cancer. Such molecules include the vascular endothelial growth factor (VEGF), the platelet derived growth factor (PDGF), the fibroblast growth factor (FGF), and the angiopoietin/Tie2 receptor complex. These proteins are key players in complex molecular pathways within the tumor cell and they have been in the spotlight of the development of anti-angiogenic molecules that may act as stand-alone therapeutics, or in concert with standard treatment regimes such as chemotherapy. The pathways involved in angiogenesis and molecules that have been developed in order to combat angiogenesis are described in this paper.
引用
收藏
页码:15885 / 15909
页数:25
相关论文
共 183 条
[1]   OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [J].
Aghajanian, Carol ;
Blank, Stephanie V. ;
Goff, Barbara A. ;
Judson, Patricia L. ;
Teneriello, Michael G. ;
Husain, Amreen ;
Sovak, Mika A. ;
Yi, Jing ;
Nycum, Lawrence R. .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) :2039-2045
[2]   Apparent beneficial effects by nab-paclitaxel in the treatment of refractory metastatic ovarian carcinoma [J].
Agheli, Aref ;
Park, Sai Chang ;
Huang, Chien-Jen ;
Wang, Jan C. .
ANTI-CANCER DRUGS, 2009, 20 (06) :525-526
[3]   Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary [J].
Ahmed, Ashour Ahmed ;
Etemadmoghadam, Dariush ;
Temple, Jillian ;
Lynch, Andy G. ;
Riad, Mohamed ;
Sharma, Raghwa ;
Stewart, Colin ;
Fereday, Sian ;
Caldas, Carlos ;
DeFazio, Anna ;
Bowtell, David ;
Brenton, James D. .
JOURNAL OF PATHOLOGY, 2010, 221 (01) :49-56
[4]   FGF-dependent Notch signaling maintains the spinal cord stem zone [J].
Akai, J ;
Halley, PA ;
Storey, KG .
GENES & DEVELOPMENT, 2005, 19 (23) :2877-2887
[5]   Lymphangiogenesis and cancer metastasis [J].
Al-Rawi, Mahir A. A. ;
Jiang, Wen G. .
FRONTIERS IN BIOSCIENCE-LANDMARK, 2011, 16 :723-739
[6]   Prognostic significance of vascular endothelial growth factor, basic fibroblastic growth factor, and microvessel density and their relation to cell proliferation in B-cell non-Hodgkin's lymphoma [J].
Alshenawy, Hanan AlSaeid .
ANNALS OF DIAGNOSTIC PATHOLOGY, 2010, 14 (05) :321-327
[7]   Role of platelet-derived growth factors in physiology and medicine [J].
Andrae, Johanna ;
Gallini, Radiosa ;
Betsholtz, Christer .
GENES & DEVELOPMENT, 2008, 22 (10) :1276-1312
[8]   Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines [J].
Apte, SM ;
Bucana, CD ;
Killion, JJ ;
Gershenson, DM ;
Fidler, IJ .
GYNECOLOGIC ONCOLOGY, 2004, 93 (01) :78-86
[9]   Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma [J].
Apte, SM ;
Fan, D ;
Killion, JJ ;
Fidler, IJ .
CLINICAL CANCER RESEARCH, 2004, 10 (03) :897-908
[10]   Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling [J].
Baffert, F ;
Le, T ;
Sennino, B ;
Thurston, G ;
Kuo, CJ ;
Hu-Lowe, D ;
McDonald, DM .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2006, 290 (02) :H547-H559